P/S ratio for Clovis Oncology (CLVS)

P/S ratio on February 22, 2023 (TTM) : 1.29

According to Clovis Oncology's latest financial reports and stock price the company's current price-to-sales ratio (TTM) is 0.0884849. At the end of 2022 the company had a P/S ratio of 1.29.

P/S ratio history for Clovis Oncology from 2011 to 2022

PS ratio at the end of each year

Year	P/S ratio	Change
2022	1.29	-45.05%
2021	2.35	-22.26%
2020	3.03	-24.48%
2019	4.01	-59.7%
2018	9.94	-83.88%
2017	61.7	-99.72%
2016	> 1000
2015	N/A	-100%
2014	140
2013	N/A
2012	N/A
2011	N/A

P/S ratio for similar companies or competitors

Company	P/S ratio	P/S ratio differencediff.	Country
BioMarin Pharmaceutical BMRN	5.25	5,835.91%	🇺🇸 USA
AstraZeneca AZN	5.01	5,560.56%	🇬🇧 UK
Pfizer PFE	3.02	3,313.73%	🇺🇸 USA
Johnson & Johnson JNJ	4.58	5,079.20%	🇺🇸 USA
AbbVie ABBV	6.22	6,927.37%	🇺🇸 USA
Eli Lilly LLY	21.2	23,822.95%	🇺🇸 USA

What is the market capitalization of a company?

The market capitalization sometimes referred as Marketcap, is the value of a publicly listed company.
In most cases it can be easily calculated by multiplying the share price with the amount of outstanding shares.

DISCLAIMER

CompaniesMarketCap is receiving financial compensation for Delta App installs.
CompaniesMarketCap is not associated in any way with CoinMarketCap.com
Stock prices are delayed, the delay can range from a few minutes to several hours.
Company logos are from the CompaniesLogo.com logo database and belong to their respective copyright holders. Companies Marketcap displays them for editorial purposes only.

Contact

For inquiries or if you want to report a problem write to hello@8marketcap.com

Links

- Privacy policy

- Terms and conditions